107793-72-6
基本信息
碘昔兰 USP标准品
Oxilan 300
IOXILAN (400 MG)
5-[Acetyl(2,3-dihydroxypropyl)aMino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-
5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
物理化学性质
| 沸点 | 827.8±65.0 °C(Predicted) |
| 密度 | 2.205±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO: ≥ 250 mg/mL (316.01 mM) |
| 酸度系数(pKa) | 11.47±0.46(Predicted) |
| 形态 | Solid |
| 颜色 | White to off-white |
| 主要应用 | pharmaceutical (small molecule) |
| InChI | 1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) |
| InChIKey | UUMLTINZBQPNGF-UHFFFAOYSA-N |
| SMILES | Ic1c(c(c(c(c1C(=O)NCC(O)CO)I)C(=O)NCCO)I)N(CC(O)CO)C(=O)C |
| EPA化学物质信息 | 1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo- (107793-72-6) |
安全数据
| WGK Germany | WGK 3 |
| 海关编码 | 2924296000 |
| 存储类别 | 11 - Combustible Solids |
碘昔兰价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-109513 | 碘昔兰 Ioxilan | 107793-72-6 | 5 mg | 1100元 |
| 2026/09/15 | HY-109513 | 碘昔兰 Ioxilan | 107793-72-6 | 10 mg | 1750元 |
| 2026/09/15 | HY-109513 | 碘昔兰 Ioxilan | 107793-72-6 | 10 mM * 1 mL in DMSO | 1914元 |
常见问题列表
As a low-osmolar nonionic monomer, Ioxilan increases the safety and tolerance of X-ray contrast agents. The development of Ioxilan is based on the introduction of a double methylene as a hydrophobic region and masking it with a hydrophilic hydroxyl group could lower the osmolality without adversely affecting the biological tolerance.
Rapid intravenous injection of water-soluble X-ray contrast agents (Ioxilan) can be performed with dynamic computed tomography to improve the detectability of liver lesions. When injected intravenously, water-soluble, intravenous X-ray contrast agents are largely distributed in the extracellular fluid space and excreted unchanged by the kidneys. Contrast enhancement of a region of interest depends on the route of administration, delivery of the agent to the area by blood flow, and the final iodine concentration in the region.